These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 16356090)
1. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma. Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090 [TBL] [Abstract][Full Text] [Related]
2. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival. Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625 [TBL] [Abstract][Full Text] [Related]
3. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan? Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184 [TBL] [Abstract][Full Text] [Related]
4. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064 [TBL] [Abstract][Full Text] [Related]
6. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma. Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520 [TBL] [Abstract][Full Text] [Related]
7. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131. Matovic MD; Jankovic SM; Jeremic M; Tasic Z; Vlajkovic M Thyroid; 2009 Aug; 19(8):843-8. PubMed ID: 19519221 [TBL] [Abstract][Full Text] [Related]
8. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma. Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148 [TBL] [Abstract][Full Text] [Related]
9. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Hodgson DC; Brierley JD; Tsang RW; Panzarella T Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma. Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760 [TBL] [Abstract][Full Text] [Related]
11. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458 [TBL] [Abstract][Full Text] [Related]
12. A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer. Bal C; Chandra P; Kumar A; Dwivedi S Nucl Med Commun; 2012 Oct; 33(10):1039-47. PubMed ID: 22760303 [TBL] [Abstract][Full Text] [Related]
13. Use of fractionated doses of iodine-131 for ablation of thyroid remnants. Wang SJ; Liu TJ Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jul; 65(7):336-40. PubMed ID: 12365652 [TBL] [Abstract][Full Text] [Related]
14. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation. Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300 [TBL] [Abstract][Full Text] [Related]
16. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. Silberstein EB J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976 [TBL] [Abstract][Full Text] [Related]
17. Outcome after high-dose radioiodine therapy for advanced differentiated thyroid carcinoma in childhood. Gao YC; Lu HK Endocr Res; 2009; 34(4):121-9. PubMed ID: 19878072 [TBL] [Abstract][Full Text] [Related]
18. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Jarzab B; Handkiewicz-Junak D; Wloch J Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322 [TBL] [Abstract][Full Text] [Related]
19. Treatment for microcarcinoma of the thyroid--clinical experience. Küçük NO; Tari P; Tokmak E; Aras G Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573 [TBL] [Abstract][Full Text] [Related]
20. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Dam HQ; Kim SM; Lin HC; Intenzo CM Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]